CA2976926A1 - Anti-pvrig antibodies and methods of use - Google Patents

Anti-pvrig antibodies and methods of use Download PDF

Info

Publication number
CA2976926A1
CA2976926A1 CA2976926A CA2976926A CA2976926A1 CA 2976926 A1 CA2976926 A1 CA 2976926A1 CA 2976926 A CA2976926 A CA 2976926A CA 2976926 A CA2976926 A CA 2976926A CA 2976926 A1 CA2976926 A1 CA 2976926A1
Authority
CA
Canada
Prior art keywords
cpa
cha
pvrig
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2976926A
Other languages
English (en)
French (fr)
Other versions
CA2976926C (en
Inventor
Mark White
Sandeep Kumar
Christopher Chan
Spencer LIANG
Lance STAPLETON
Andrew W. DRAKE
Yosi GOZLAN
Iian VAKNIN
Shirley Sameah-Greenwald
Liat Dassa
Zohar Tiran
Gad S. Cojocaru
Leonard Presta
Richard Theolis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Compugen Ltd
Original Assignee
Compugen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55453315&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2976926(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Compugen Ltd filed Critical Compugen Ltd
Publication of CA2976926A1 publication Critical patent/CA2976926A1/en
Application granted granted Critical
Publication of CA2976926C publication Critical patent/CA2976926C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
CA2976926A 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use Active CA2976926C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562118208P 2015-02-19 2015-02-19
US62/118,208 2015-02-19
US201562141120P 2015-03-31 2015-03-31
US62/141,120 2015-03-31
US201562235823P 2015-10-01 2015-10-01
US62/235,823 2015-10-01
PCT/US2016/018809 WO2016134333A1 (en) 2015-02-19 2016-02-19 Anti-pvrig antibodies and methods of use

Publications (2)

Publication Number Publication Date
CA2976926A1 true CA2976926A1 (en) 2016-08-25
CA2976926C CA2976926C (en) 2025-12-02

Family

ID=

Also Published As

Publication number Publication date
US20160244521A1 (en) 2016-08-25
US9714289B2 (en) 2017-07-25
HK1247568A1 (en) 2018-09-28
US20200148769A1 (en) 2020-05-14
MX2020009461A (es) 2021-02-17
KR102669294B1 (ko) 2024-05-23
ES2929293T3 (es) 2022-11-28
US20210188974A1 (en) 2021-06-24
HK1247569A1 (en) 2018-09-28
DK3653221T5 (da) 2024-08-26
HRP20200572T1 (hr) 2020-08-21
MX2017010667A (es) 2018-08-15
CY1123259T1 (el) 2021-12-31
DK3653221T3 (da) 2022-10-24
EP4129320A1 (en) 2023-02-08
MX374853B (es) 2025-03-06
LT3295951T (lt) 2020-09-25
HUE049032T2 (hu) 2020-08-28
US10227408B2 (en) 2019-03-12
RU2017132214A3 (OSRAM) 2019-08-28
KR20170137067A (ko) 2017-12-12
IL254039B1 (en) 2023-08-01
SI3258951T1 (sl) 2020-07-31
CN107580500A (zh) 2018-01-12
EP3258951A1 (en) 2017-12-27
ES2806800T3 (es) 2021-02-18
JP2018512443A (ja) 2018-05-17
EP3295951B1 (en) 2020-04-22
AU2024202336A1 (en) 2024-05-16
CN107580500B (zh) 2023-05-30
IL304117A (en) 2023-09-01
US20180244774A1 (en) 2018-08-30
IL254039B2 (en) 2023-12-01
JP2022106783A (ja) 2022-07-20
HRP20201066T1 (hr) 2021-02-05
US10351625B2 (en) 2019-07-16
EP3295951A1 (en) 2018-03-21
US20170029504A1 (en) 2017-02-02
CY1122970T1 (el) 2021-10-29
RU2020128686A (ru) 2020-10-13
SG11201706583PA (en) 2017-09-28
US11623955B2 (en) 2023-04-11
US11220542B2 (en) 2022-01-11
PT3653221T (pt) 2022-11-08
SI3295951T1 (sl) 2020-10-30
EP3653221B1 (en) 2022-08-03
AU2020264349A1 (en) 2020-12-03
HUE049791T2 (hu) 2020-10-28
US20250333503A1 (en) 2025-10-30
LT3258951T (lt) 2020-05-11
PT3258951T (pt) 2020-08-18
PL3258951T3 (pl) 2020-07-27
DK3295951T3 (da) 2020-07-20
LT3653221T (lt) 2022-11-10
PL3295951T3 (pl) 2020-10-05
EP3653221A1 (en) 2020-05-20
US11795220B2 (en) 2023-10-24
AU2016219835B2 (en) 2020-12-03
US20170081408A1 (en) 2017-03-23
RU2732042C2 (ru) 2020-09-10
IL254039A0 (en) 2017-10-31
EP3258951B1 (en) 2020-01-29
RU2017132214A (ru) 2019-03-19
US12312404B2 (en) 2025-05-27
WO2016134333A1 (en) 2016-08-25
US20240101669A1 (en) 2024-03-28
ES2786651T3 (es) 2020-10-13
HUE061084T2 (hu) 2023-05-28
PT3295951T (pt) 2020-07-21
AU2016219835A1 (en) 2017-09-14
JP7115856B2 (ja) 2022-08-09
KR20240090732A (ko) 2024-06-21
AU2020264349B2 (en) 2024-05-02
CN115350275A (zh) 2022-11-18
DK3258951T3 (da) 2020-04-06
ZA201706323B (en) 2020-05-27
PL3653221T3 (pl) 2022-12-19
WO2016134333A9 (en) 2017-02-02
HRP20221284T1 (hr) 2022-12-23

Similar Documents

Publication Publication Date Title
US12312404B2 (en) Anti-PVRIG antibodies and methods of use
HK40082328A (en) Anti-pvrig antibodies and methods of use
CA2976926C (en) Anti-pvrig antibodies and methods of use
RU2827926C2 (ru) Анти-pvrig антитела и способы применения
HK40084573A (zh) 抗pvrig抗体和使用方法
HK40020102B (en) Anti-pvrig antibodies and methods of use
HK40020102A (en) Anti-pvrig antibodies and methods of use
HK1247569B (en) Anti-pvrig antibodies and methods of use
HK1247568B (en) Anti-pvrig antibodies and methods of use

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210219

EEER Examination request

Effective date: 20210219

EEER Examination request

Effective date: 20210219

EEER Examination request

Effective date: 20210219

EEER Examination request

Effective date: 20210219

EEER Examination request

Effective date: 20210219

EEER Examination request

Effective date: 20210219